Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
With their diverse biological activities, peptides are promising candidates for therapeutic applications, showing antimicrobial, antitumour and hormonal signalling capabilities. Despite their advantages, therapeutic peptides face challenges such as short half-life, limited oral bioavailability and susceptibility to plasma degradation. The rise of computational tools and artificial intelligence (AI) in peptide research has spurred the development of advanced methodologies and databases that are pivotal in the exploration of these complex macromolecules. This perspective delves into integrating AI in peptide development, encompassing classifier methods, predictive systems and the avant-garde design facilitated by deep-generative models like generative adversarial networks and variational autoencoders. There are still challenges, such as the need for processing optimization and careful validation of predictive models. This work outlines traditional strategies for machine learning model construction and training techniques and proposes a comprehensive AI-assisted peptide design and validation pipeline. The evolving landscape of peptide design using AI is emphasized, showcasing the practicality of these methods in expediting the development and discovery of novel peptides within the context of peptide-based drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
UniProt: the Universal Protein Knowledgebase in 2023
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., Bye-A-Jee, H., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1052 · Cited by 7,210
Accurate prediction of protein structures and interactions using a 3-track network
Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., Wang, J., Cong, Q., Kinch, L. N., Schaeffer, R. D., et al. (2021) · doi:10.1101/2021.06.14.448402 · Cited by 5,549 · cited 1×
“…bioinformatics, DL has allowed the development of predictive models to estimate protein–protein interactions, classification systems for unknown enzymes through recognition of enzyme commission numbers [57] and predictive systems for protein structures such as RoseTTAFold [58] or AlphaFold [59].”
MethodDrug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Generative Adversarial Networks: An Overview
Creswell, A., White, T., Dumoulin, V., Arulkumaran, K., Sengupta, B., & Bharath, A. A. (2018) · IEEE Signal Processing Magazine · doi:10.1109/msp.2017.2765202 · Cited by 4,540 · cited 1×
“This process continues until the generator produces samples that the discriminator is not able to differentiate from real data [101, 102].”
BackgroundInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“This process can often take decades and has a cost that can exceed a billion US dollars per target [84], considering that most drugs do not reach the market [85].”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2022) · doi:10.1101/2022.12.09.519842 · Cited by 2,369 · cited 1×
“Another relevant method for peptide therapeutic peptide design is the combination of structure prediction networks with diffusion generative approaches [127].”
MethodDe novo design of protein structure and function with RFdiffusion
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06415-8 · Cited by 2,325
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 1×
“This section aims to offer a perspective on peptides, exploring their multifaceted biological functions, moonlighting attributes and applications [13, 14].”
BackgroundDundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., & Liang, J. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl282 · Cited by 1,725 · cited 1×
“It also uses data from PDB for 3D structures, Uniprot for the names of interacting proteins or peptides and CASTp to calculate protein pockets [118, 119].”
MethodDeep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473 · cited 1×
“In addition to the different learning types, two main focuses have been implemented for developing models using ML strategies, classic ML approaches and deep learning (DL) architectures [55].”
MethodA Review on Generative Adversarial Networks: Algorithms, Theory, and Applications
Gui, J., Sun, Z., Wen, Y., Tao, D., & Ye, J. (2023) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2021.3130191 · Cited by 1,231
Transfer learning enables predictions in network biology
Theodoris, C. V., Xiao, L., Chopra, A., Chaffin, M. D., Al Sayed, Z. R., Hill, M. C., Mantineo, H., Brydon, E. M., Zeng, Z., Liu, X. S., et al. (2023) · Nature · doi:10.1038/s41586-023-06139-9 · Cited by 1,193 · cited 1×
“The applications of transfer learning approaches by applying foundational trained models to biology context have demonstrated usability to develop efficient predictive models [60].”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Elucidating the Design Space of Diffusion-Based Generative Models
Karras, T., Aittala, M., Aila, T., & Laine, S. (2022) · arXiv · doi:10.48550/arxiv.2206.00364 · Cited by 702
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
AI for life: Trends in artificial intelligence for biotechnology
Holzinger, A., Keiblinger, K., Holub, P., Zatloukal, K., & Müller, H. (2023) · New Biotechnology · doi:10.1016/j.nbt.2023.02.001 · Cited by 438
Chen, S., Lin, T., Basu, R., Ritchey, J., Wang, S., Luo, Y., Li, X., Pei, D., Kara, L. B., & Cheng, X. (2024) · Nature Communications · doi:10.1038/s41467-024-45766-2 · Cited by 324
Discovering highly potent antimicrobial peptides with deep generative model HydrAMP
Szymczak, P., Możejko, M., Grzegorzek, T., Jurczak, R., Bauer, M., Neubauer, D., Sikora, K., Michalski, M., Sroka, J., Setny, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36994-z · Cited by 231 · cited 3×
“Using HydrAMP, AMPs, including a superior analogue (Hydraganan-1) of Pexiganan, were generated and experimentally tested against E. coli strains [111].”
Lien, S., & Lowman, H. B. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.10.005 · Cited by 209 · cited 1×
“Peptides consist of short chains of amino acids, with a molecular weight ranging from 0.5 to 10 kDa [15], and a length ranging from a couple of amino acids up to 100 [16].”
BackgroundInfluentialBurbach, J. P. H. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-310-3_1 · Cited by 167
Protein design via deep learning
Ding, W., Nakai, K., & Gong, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac102 · Cited by 66
Revolutionizing peptide‐based drug discovery: Advances in the post‐AlphaFold era
Chang, L., Mondal, A., Singh, B., Martínez‐Noa, Y., & Perez, A. (2024) · WIREs Computational Molecular Science · doi:10.1002/wcms.1693 · Cited by 56 · cited 1×
“Additionally, the advances in structure predictions supported by AlphaFold have generated a new era for peptide-based drug discovery, facilitating the generation or discovery of new therapeutic peptides [131].”
Background
Cited by
Peptipedia v2.0: a peptide sequence database and user-friendly web platform. A major update
Cabas-Mora, G., Daza, A., Soto-García, N., Garrido, V., Alvarez, D., Navarrete, M., Sarmiento-Varón, L., Sepúlveda Yañez, J. H., Davari, M. D., Cadet, F., et al. (2024) · Database · doi:10.1093/database/baae113 · Cited by 35
Self-citation
Metadata
- Authors
- Goles, M., Daza, A., Cabas-Mora, G., Sarmiento-Varón, L., Sepúlveda-Yañez, J., Anvari-Kazemabad, H., Davari, M. D., Uribe-Paredes, R., Olivera-Nappa, Á., Navarrete, M. A., & Medina-Ortiz, D.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-05-23
- Volume
- 25
- Issue
- 4
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W4399497299
- Cited by
- 168
- References
- 26
- FWCI
- 32.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.